INBS Investor Deck Confirms FDA 510(k) Submission on Track for H2 2026
INBS sits 55% above its 52-week low of $1.52 on light trading volume (0.2× avg).
Summary
Intelligent Bio Solutions published an investor presentation confirming its FDA 510(k) submission is on track for H2 2026, with clearance expected in HY 2027. The deck also discloses a manufacturing partnership expected to deliver >40% production cost savings and a ~20 percentage point gross margin improvement.
Key Events · Product Development and Regulatory · INBS
-
FDA 510(k) Submission on Track for H2 2026
Investor presentation confirms all clinical data collection is complete and the 510(k) submission package for opiate codeine detection is planned for H2 2026, with FDA clearance expected in HY 2027.
-
Manufacturing Partnership to Cut Costs
Syrma Johari manufacturing partnership is expected to deliver >40% annual production cost savings and a ~20 percentage point improvement in gross margins.
-
Capital Structure Disclosed
Presentation shows 2,905,603 common shares issued, 894,425 pre-funded warrants, 3,800,028 total common equivalent shares, and 5,223,868 warrants with a weighted average exercise price of $6.51 — no ratchets or resets.
-
Commercial Traction
Company reports 1,800+ installed readers and 500+ active customer accounts across 35 countries and territories.
Analysis · INBS · Industrial Applications And Services
The investor presentation confirms the company's FDA 510(k) submission for its fingerprint drug screening system remains on track for H2 2026, with clearance expected in HY 2027. This is the first consolidated disclosure of the full clinical study completion status, anticipated regulatory timeline, and updated capital structure. The presentation also reveals a manufacturing partnership with Syrma Johari expected to cut production costs by over 40% and improve gross margins by roughly 20 percentage points — a meaningful operational milestone for a company with a going concern warning and $12.4M net loss.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBS was trading at $2.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $1.52 to $24.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.